These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 318225)
1. The fetid foot: lower-extremity infections in patients with diabetes mellitus. Fierer J; Daniel D; Davis C Rev Infect Dis; 1979; 1(1):210-7. PubMed ID: 318225 [TBL] [Abstract][Full Text] [Related]
2. Anaerobic bacteria isolated from foot infections in diabetic patients: in vitro susceptibility to nine antibiotics. Ginunas VJ; Canawati HN; Sapico FL Clin Ther; 1984; 6(4):457-60. PubMed ID: 6467279 [TBL] [Abstract][Full Text] [Related]
3. Treatment and long-term follow-up of foot infections in patients with diabetes or ischemia: a randomized, prospective, double-blind comparison of cefoxitin and ceftizoxime. Hughes CE; Johnson CC; Bamberger DM; Reinhardt JF; Peterson LR; Mulligan ME; Gerding DN; George WL; Finegold SM Clin Ther; 1987; 10 Suppl A():36-49. PubMed ID: 3319172 [TBL] [Abstract][Full Text] [Related]
8. Pathogenicity of capsulate and non-capsulate members of Bacteroides fragilis and B. melaninogenicus groups in mixed infection with Escherichia coli and Streptococcus pyogenes. Brook I J Med Microbiol; 1988 Nov; 27(3):191-8. PubMed ID: 2903934 [TBL] [Abstract][Full Text] [Related]
10. Aspects on antibacterial treatment of anaerobic infections. Nordbring F; Nord CE Scand J Infect Dis Suppl; 1982; 35():59-62. PubMed ID: 6762654 [TBL] [Abstract][Full Text] [Related]
11. Cefoxitin therapy in aerobic, anaerobic, and mixed aerobic-anaerobic infections. LeFrock JL; Schell RF; Carr BB; Kowalsky SF; Tillotson JR Drug Intell Clin Pharm; 1982 Apr; 16(4):306-12. PubMed ID: 7067621 [TBL] [Abstract][Full Text] [Related]
12. Cefoxitin for treatment of infections due to anaerobic bacteria. Kirby BD; Busch DF; Citron DM; Finegold SM Rev Infect Dis; 1979; 1(1):113-7. PubMed ID: 318212 [TBL] [Abstract][Full Text] [Related]
13. Comparative study of piperacillin versus cefoxitin in the treatment of obstetric and gynecologic infections. Sweet RL; Robbie MO; Ohm-Smith M; Hadley WK Am J Obstet Gynecol; 1983 Feb; 145(3):342-9. PubMed ID: 6218755 [TBL] [Abstract][Full Text] [Related]
14. The infected foot of the diabetic patient: quantitative microbiology and analysis of clinical features. Sapico FL; Witte JL; Canawati HN; Montgomerie JZ; Bessman AN Rev Infect Dis; 1984; 6 Suppl 1():S171-6. PubMed ID: 6718934 [TBL] [Abstract][Full Text] [Related]
15. Effect of prophylactic antibiotics upon mixed infections with Bacteroides fragilis. Brook I Surg Gynecol Obstet; 1987 Dec; 165(6):491-5. PubMed ID: 3317944 [TBL] [Abstract][Full Text] [Related]
17. [Bacteriological and clinical evaluation of cefoxitin in the treatment of infections in 39 obstetric and gynecological patients]. Kaseki S; Mano T; Tomoda Y; Kazato S; Asai Y; Sahara K; Manba S; Maruyama T; Kasugai M; Higashide K; Sekiya H; Mizutani S; Watanabe K; Ueno K Jpn J Antibiot; 1983 Mar; 36(3):509-21. PubMed ID: 6876361 [TBL] [Abstract][Full Text] [Related]
18. Microbiological studies of tracheostomy site wounds. Brook I Eur J Respir Dis; 1987 Nov; 71(5):380-3. PubMed ID: 3502089 [TBL] [Abstract][Full Text] [Related]
19. Microbiology of superficial and deep tissues in infected diabetic gangrene. Sharp CS; Bessmen AN; Wagner FW; Garland D; Reece E Surg Gynecol Obstet; 1979 Aug; 149(2):217-9. PubMed ID: 462355 [TBL] [Abstract][Full Text] [Related]
20. In vitro activity of flomoxef compared to moxalactam, cefoxitin, cefotaxime, and clindamycin against anaerobes. Werner H; Heizmann W; Luft G Arzneimittelforschung; 1988 Nov; 38(11):1553-6. PubMed ID: 3214438 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]